New combo shows promise for bladder cancer patients who can't take standard chemo
NCT ID NCT04553939
First seen Jan 08, 2026 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tested a combination of two drugs (toripalimab and gemcitabine) given before surgery to people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. The goal was to see how well the drugs shrink tumors before the bladder is removed. The study enrolled 50 adults aged 18-75 with stage II-IIIB bladder cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.